Tag:

Lipitor

Latest Headlines

Latest Headlines

AstraZeneca, Pfizer say direct-delivery programs can win with patients

Time is running out before generics descend on Nexium, the stomach drug that rakes in nearly $4 billion a year for AstraZeneca. And in an effort to conserve sales, the British drugmaker is going where it's gone once before: a direct-to-patient delivery program it hopes will keep customers in its grasp.

Statins and muscle aches are unrelated

So is Lipitor or Crestor causing you to have muscle aches? The answer is no, according to a new meta-analysis of the side effects of the cholesterol-lowering drugs.

Ranbaxy issues a recall, but so do Pfizer, Baxter, Gilead and Mylan

India's Ranbaxy Laboratories has issued another recall for its generic Lipitor, but a series of product recalls in recent weeks have come from plants around the world and companies as varied as Pfizer, Mylan and Gilead Sciences.

Pfizer keeps rolling with $1B bid for OTC Lipitor

Pfizer's once-gargantuan statin drug Lipitor has been cut down to size by generic competition. But if the drugmaker's plan to win over-the-counter status for the drug succeeds, Pfizer could add up to $1 billion back into its Lipitor franchise.

Teva, Ranbaxy settle case for sidestepping each other's launches

Teva Pharmaceutical Industries and Ranbaxy Laboratories only have to pay $300,000 in a new "pay-for-delay" settlement with the state of New York over their arrangement on generic Lipitor. But the agreement also prevents the two from sidestepping each other on dozens of other drugs, opening up the possibility of greater generic competition.

Antitrust watchdogs come down on Pfizer for Lipitor dealmaking

The antitrust crackdown in pharma has moved to Australia. Once again, Pfizer finds itself in the middle of a legal fight over its efforts to hang onto Lipitor sales after the drug went off patent and faced competition from cheaper generics.

Pfizer's slim-down boosts earnings as Lipitor losses put a damper on sales

Pfizer is on a diet, and it shows. The company pumped up 2013 earnings despite a sizable slide in sales, thanks to layoffs and cost cuts, not to mention the successful spinoff of its animal health business, Zoetis. And it's looking for more of the same for 2014.

FDA extends Ranbaxy consent decree to Mohali plant

The FDA said in an announcement Monday that it had placed the Mohali plant on import alert after inspections in September and December of last year found significant cGMP violations. The agency said the plant will now have to conform to provisions of a consent decree that Ranbaxy agreed to last year, which initially was written to cover its Paonta Sahib and Dewas facilities.

Study: Pharma payments do sway doctors' prescribing habits

A new study shows that payments do influence doctors' behavior. The average amount that flows from pharma to physician is about $1,700 per. Still, doctors are swayed by free dinners and speaking fees, the study finds, with prescriptions rising along with payments.

Pfizer quells fears of cuts at Ireland plant that makes Viagra

The plant in Ireland that manufactures Viagra isn't slated for any cutbacks despite Pfizer's patent loss on the erectile dysfunction blockbuster in the U.K. and Europe.